ƒ„…†‡ˆ‰Š
`
`‹„Œ†Žˆ
`  
` 
` 

"
`
`0€@4@4564‚E6
`€@4@444@}@6
`    
` 

 
`
`  
`

 
`   
` 
`  
`
`   
` 
`
`    
`
`
`
` 
` 
`    ! 
` ! 
`    "!
`  
`
`
`#
`$% & 
`'
`    "  !$      
` 
`
`

`
`
` ()*+,-.,*+/ 
`
`
`  0 1   
` 1 
`1
`
`'  
`   "! 2"

 
`      ! 

  
`
`   
`

  
`
`30 456% 3"

7.).8()89)*+::+;*<.:=,>-+,*?   ! 2"

'
`
`@666 
`3 
`  AB
`
` 
` C 
`  
`
`
` !
`3  3&
`

`
`   3   3  
` 3  3
` 3"

`!  D  
`
`
`
`3      
` !
`   

`!"   !
` 
`
`   " 3    
` 46@E 3#
`$% & 
` !
`
` 3"

`D 
` '  
`   "! 2 
`  
`
`
` !
` "

`! 566#
`
` 
`

`
` 1 
`1
`'   F(>8+)9GHIJ9); K+)+)*+;LMNK:.O>PQ(*LR:()+
`  
`  
` "

`

'2 S  
` 
`3
`
` 
`1 
`
` 3"

`D  ' 
`      
`   "  !
` 
`    
`! T   
`  
` " ! 
`
`
`
`#UV'W   
`
`  2 
`$ 
`    
`  #
`! 




`  
` "  
`W' X'    
`

   
`#   
`    
`  
` ! 
`    "!
`  
`
`
`
`#
`$% & '
` 

 "

""
`! ! 
`
`
`
`''   
` 
`$  !()*+,-.,*+/   
` 
`
`
` !
` 
` !
`
`
` !  
`!&  S$$  
` 
`3  3X"
`0' 
`  
`
`
`
`
` !
`   !
` !" !  
`  !  
` 
` "


` !
`   !
`$31 " 

3
`
` 
` 
`    Y
` 
` Z 
`

 
` 
`
`
` !
` 
`   $ 
` !" %  1
`
`
`[&  
`\]^_]`]abcbde]fdbdgcbdhacaij_dcklm^]_d]an]
`o  #
`$% & 
`
`
` !
`   ! 
`
`
`0 &SpI+-L.:>).)q
`7+Q>,(.:P:>.)rR+**+,()8I.);+,I+)*+,MNs,+/+)(</R.t( WWu
`o  
`
`  !
`
`  ! 
`
`
`[
`Spv./L()8*>)w+/+.,;L
`s><)q.*(>).)qK+)+)*+;LMNP.)>x(JP.)>x(rP?)*L+:.t>yyIJ.)qP.)>x(rzM+)*(/ %W% u
`o  
`
`  !
`
`  ! 
` {
`p1|{}u 
` "

`

` 
`SpP.)>x(.)qw+8+)+,>)MNK+)+)*+;L.)qI(*?>x~>-+ 1W1 u  
`9)*+,
`=.,*+/ "
`Z
`
` 0   pP.)>x(.)qw+8+)+,>)MNK+)+)*+;L.)q
`–——˜™š’’›œ„Œ†ˆ›žˆœ’˜†ˆ˜Ÿ†’ †—„¡Ÿ˜¡—›„™˜¢£„——ˆ†Œ¤Š”¥
`‘’‡“’‘”‡•
`
`

`
`‹„Œ†Žˆ
`ƒ„…†‘ˆ‰Š
`I(*?>x~>-+ Z0u
`o  #
`$% & 
`
`
` !
`   !#U
`

&  Sp¦((¦~+.:*L;.,+.)q
`¦+,*+O=L.,Q.;+<*(;.:/MN7?:.) WWu  
`9)*+,=.,*+/ "
`Z
`
`
` 0   pw.)t.O?MN¦+,*+O=L.,Q.;+<*(;.:/ y<-()MN¦+,*+O=L.,Q.;+<*(;.:/
`Z0u
`o  " 
`
`
`  !
`
`  ! 
` "

` ["
`&S 

S
`pF,(/*>:{7?+,/P§<(ttMNK+)+)*+;L.)qI(*?>x~>-+ 1W1 u
`oX 
` ! 
`   
`   

[! 
` #
`{% & 
` !
` 
` !
`
`
` p  &Su  ! ¨pH8.:+*MNz->*+O W¨u
`o  
`
`  !
`
`  !
` 
` "


`'2 S 
`
`
`
`
` 

 

`  pF(>8+)9q+;J9);N.)qK+)+)*+;LMNK:.O>PQ(*LR:()++*.:
`W1 u
`o  " 
`
`
`  !
`
`
` !
`
`©1 " 

ª 
`   !
`
`  
` " '2 S  


` SpK:.O>K,><-y*qJK:.O>PQ(*LR:()+.)qy>)«.F(>:>8(;/
`MNK+)+)*+;L.)qI(*?>x~>-+ 1W1 ¬K+)+)*+;L9);NMNK:.O>K,><-y*q K:.O>PQ(*LR:()+.)q
`~<Q.)K+)>Q+P;(+);+/ 1W1 u
`o    
`
` 
`  
` !
` 
` !
`   
`p­+/*9=~>:q()8/yyI+*.:NMN9Q-:.)*G(,+;*+*.:¬W1 u
`o    
`  !   
`
` 
`     
`p9Q-:.)*
`G(,+;*P?t,>)MN­+/*9=~>:q()8/.)q­+/*z);L>,/¬W1 u
`o  
`
`  !
`
` 
`
`  
` !
`   
`pI>t,.s(O.*(>)/I(+y*+®¯I>t,.z);L>,/MN°+±+::²-+,.*()8I>¬W1u
`o

 
`D &
`|  
`   
`
`  !
`
`"!
`
` ! 
`!  !
`""
`!³ SpK:.O>K,><-y(Q(*+q.)qPQ(*LR:()+F++;L.Q
`I>,-NMN´+M.=L.,Q.;+<*(;.:/J9); WW¬K:.O>K,><-y(Q(*+q.)qPQ(*LR:()+F++;L.QI>,-NMNG,N
`w+qq?µ/y.t>,.*>,(+/J9); W¨¬K:.O>K,><-y(Q(*+q.)qPQ(*LR:()+F++;L.QI>,-NMNR.:(
`y.t>,.*>,(+/ W¨¬K:.O>K,><-y(Q(*+q.)qPQ(*LR:()+F++;L.QI>,-NMN=:(M. W¨¬K:.O>K,><-
`y(Q(*+q.)qPQ(*LR:()+F++;L.QI>,-NMNP.)q>« W¨u
`oX 
` 2 
`  
`
`  !
`
`"!
` ! 
`! 
` !
`1  S!p=x(«+,9);NMNz->*+OI>,- Wu
`oX 
`   $" 
`!

 


`
`
` !
`   !
`  ! 

`
` 
`pH:.)I>,-NMNI?8)</´L+,.-+<*(;/ W1 u
`oX 
`
`!  
`  
` $
`
`  !
`
`
` !
` " 
`  !  !
`   ! !
`!

pP?Qt>:´+;L)>:>8(+/MN7+*,>:>8(;9)/*,<Q+)*/ [W0&u
`oX 
` Y  
` $  
` !
`  
` 
`
` !
` 
`p°.)>)+OI>,-NMNP+.8.*+´+;L)>:>8? W¨u
`oX 
` 
`
`" $ 


`    !
`
` !
` pK,++)=>()*
`s().);(.:MNP-+,,?~<*;L()/>) Wu
`oX 
`
`
` " 
`
`
`  !
`
`p¶()+*(;J9);NMNI>-(+)*
`´+;L)>:>8(+/JyyI Wu
`oX 
`
`    !
` 
`  
`  
`    !
`
`
`pw+/+,M+7.).8+Q+)*I>,-NMNw+/+,M+9); Wu
`\]^_]`]abcbde]·^^]kkcb]lm^]_d]an]
`o9Q-:.)*G(,+;*MN­+/*z);L>,/.)q­+/*9=~>:q()8 '  46@5$@}4¸p1 u
`oF(>8+)9GHI.)qK+)+)*+;L9);NMNK:.O>PQ(*LR:()+yyI.)qK:.O>K,><-y*qN '  46@4$@@46
`p1 u
`o7+*,>:>8(;9)/*,NMN9)*µ:´,.q+I>QQN '  6¸$@5¹4p1 u
`oP?Qt>:´+;L)>:>8(+/MN9)*µ:´,.q+I>QQN '  6¸$@E¸4p1 u
`oK:.O>K,><-y*qNMNR.:(y.t/N '  6$@64p1 u
`os+,,()8=L.,QNMNF.,,y.t/N '  65$@4¹Ep1 u
`oK:.O>K,><-y*qNMN´+M.=L.,QN '  65$@65¸p1 u
`o7.,/L.ºMN´,+.q±+:: '  }}$5¸¹ 5@Ep‚1 u
`o°./L<.I>NMNw(;>LJ+*.:N }¹$@¹¸4pZ 1
`u
`[
` 
`o
`# Z 
`

 ¨W¬[
`
`
`#  X 
`oZ 
`

U !  '
`–——˜™š’’›œ„Œ†ˆ›žˆœ’˜†ˆ˜Ÿ†’ †—„¡Ÿ˜¡—›„™˜¢£„——ˆ†Œ¤Š”¥
`
`‘’‡“’‘”‡•
`
`

`
`ƒ„…†Áˆ‰Š
`
`Page 3 of 4
`
`Mayer Brown
`
`Ad missions
`
`o New York
`
`o New Jersey
`o US District Court for the District of New Jersey
`o US District Court for the Southern District of New York
`o US District Court for the Eastern District of New York
`
`o US Court of Appeals for the Federal Circuit
`o US Court of Appeals for the Second Circuit
`o US Court of Appeals for the Third Circuit
`o US Supreme Court
`o US Court of International Trade
`
`Activities
`
`Member of the American Bar Association, Litigation and Intellectual Property Law sections
`Member of the New York State Bar Association, Intellectual Property Law section
`Intellectual Property Owners Association, Litigation Committee, NYIPLA and AIPLA
`Member New York Intellectual Property Law Association
`Member American Intellectual Property Law Association
`Board Member, Women in Law Empowerment Forum (WILEF)
`
`News & Publications
`
`‹„Œ†Žˆ
`'  
`o
`o¨

`oZW 
` 
`1
`
`W 
` 
`¨

`oZW 
` 
`1
`
`
`W 
` 
`
`oZW 
` 
`1
`
`[ 
`W 
` 
`
`oZ1
`'  
` 1 
`
`oZ1
`'  
`1 
`
`oZ1
`'  
`0 1 
`
`oZ 1
`
`oZ1
`
`
`  0 
`'
` 
` 
`o"
`'   '
` 
` !
`  
`
`  
`


` 
`o"
`
`
` '
`  
`
`  
`


` 
`o
`
`  
`

'
` 
` !
` 1
`
` ' ''
`o"
`
`  
`

'
` 
`o"'  
`
`  
`

'
` 
`o  " %  [ 
`p%[u
`»" 
` 
`o350 0'  
`  
`  3 ‚6 ‚W"46@5
`o30W
` [C  
` 
`1 !D  !  !
`¼¼"
` 
` ½½ 
`
`¨

`0  3 "! '
`
` 0  »1

 !
`¨  @
`"46@5
`o3'
`
`

' 
`$
` ¾'D  
`
`  3 1 4‚
`"46@5
`o3 !
`
`$ 
` 
` 
` !
` 
`
`!

U 

W  !U 
`

3
` 1 @
`"46@5
`o3

  
`

`
`Z0U U# 
`  U
`&  
`   #
`$
`% & 
` 
`X  3@6¨

46@5
`o3

  
`! 2"

9z7=.*+)*¿ÀÀÀ 3@¸¨46@5
`o30

  
`! 2 ©
` ª 7.).8()89=µ/46@5%# " 
`

34¹

46@5
`o3

  
`   0 D   
` 
`©0 456% ª 3‚6
`
`"46@E
`o3

  
`   0 D   ©¾#
`$% & p  u
` !
`
`
` ª   
`D  '  34}¨

46@E
`o3' !
`
`$

  

   3 ¨  @‚¨  

46@E
`o3 Z 
`¾ 1 
`1
`'C
` "1
`1 
`¬D  !
`
`
`'  
` ´L+,./+)/+
`   3

 ! Z 
` ¹¨  

46@E
`o3 Z 
`¾"Y
`   $"  0X   ½" 
`W
` 
`  3

 ! Z 
` @
`"46@‚
`o3

  
`   0 D   
` !
` 456  
`
`   
`

`  3@
`"46@‚
`o3

 
`
`

 D46@‚3  
` 3 3@¨

46@‚
`o3

  
`   !   ! !½46@‚%# " 

3@

`46@‚o3D| 

1  W!
`
`
` 3 ‚6 @'  46@‚
`o3

  
` 
`

D| 
`
`  !
`  3@'  46@‚
`o3X


`
`
`
`
`
`¾0
` 

'
`
`
` 
`
`   3
`
` 
` 
`

»0!

¨ 
`o30  X !
`D

 
`W! 
` 3%[X 
`o3
`
` !'! 
`   
`
` ¾W!1  
`0    
` 
` 
` 3
`   ¨  # 
`1 
` 
`o3' !
`U  
`X


`

   ! 3%[
`
`  
`o3 
` !%
` '
`½1 
` 3U
`1
` ¨ 
`–——˜™š’’›œ„Œ†ˆ›žˆœ’˜†ˆ˜Ÿ†’ †—„¡Ÿ˜¡—›„™˜¢£„——ˆ†Œ¤Š”¥
`‘’‡“’‘”‡•
`
`"5 Tips To Avoid Spoliation Sanctions," Law360, 3 December 2015
`"The Doctrine of Equivalents and the Challenge of Giving Meaning to "Substantial” in Patent Jury
`Trials," Bloomberg BNA's Patent, Trademark & Copyright Journal, 16 October 2015
`"Attorney's Fee Awards Post-Octane: A Guide for Practitioners," |nsideCounsel, 23 September 2015
`"Prepping for Battle - Best Practices for IP Litigation Strategy Vary Depending on Venue and Industry,"
`|nsideCounse|, 1 September 2015
`"Mayer Brown secures victory at the USPTO for ViiV Healthcare and Vertex Pharmaceuticals in Hatch-
`Waxman Inter Partes Review," 10 July 2015
`"Mayer Brown partners recognized by IAM Patent 1000," 17 June 2015
`"Ten Mayer Brown partners recognized as ''IP Stars” in Managing /P's 2015 World IP Handbook and
`Survey," 28 May 2015
`"Mayer Brown partners Lisa Ferri and Terri Gillis named to list of '"|'op 250 Women in IP’’,'' 30
`September 2014
`"Mayer Brown partners Lisa Ferri and Terri Gillis named "|P: Hatch-Waxman (Branded) Litigator ofthe
`Year” finalists for LMG Life Sciences Awards," 29 July 2014
`"Assessing the Post-'Myriad' and 'Mayo' Landscape," New York Law Journal, 13 January 2014
`''IP Law Update: Federal Circuit Court Allows Inequitable Conduct Claim to Proceed; Gives Insight Into
`Application of Therasense Standard," Mayer Brown Legal Update, 8 January 2014
`''IP Law Update: Objective Indicia of Non-Obviousness Lead To Reversal of Board's Obviousness
`Determination," Mayer Brown Legal Update, 16 October 2013
`"Mayer Brown partners Lisa Ferri and Terri Gillis listed among top 250 women in intellectual property
`law,'' 1 October 2013
`"Mayer Brown attorneys honored as LMG 2013 "Life Sciences Stars"," 1 July 2013
`"Mayer Brown receives top rankings in Managing |P’s 2013 World IP Handbook and Survey," 16 May
`2013
`
`"GSK Backed By Fed. Circ. In Leukemia Drug Patent Suit," Law360, 16 April 2013
`"Mayer Brown secures appellate victory for GSK in patent infringement case," 16 April 2013
`"Reverse Payment Patent Settlements: The Interplay of Antitrust and Patent Policies," Intellectual
`Property & Technology Law Journal,
`"Trademark Rights v. Gray Market Drug |mports," MWE IP Review,
`"Protecting Against Parallel Importation: Drug Companies Look to Trademark Laws, Licenses to Bar
`Imports," National Law Journal, Health Care Section,
`"Assessing the Value of Biotech Royalty Financing," MWE International News,
`"Partnering With IP, An Investor's Checklist," Venture Capital Journal,
`
`https://wvvw.mayerbrown.com/people/detailprint.aspx?attomey=409
`
`2/18/2016
`
`

`
`Mayer Brown
`
`Events
`
`ƒ„…†Šˆ‰Š
`
`Page 4 of 4
`
`‹„Œ†Žˆ
`[
`
`o

  ¾#
`0      ‚6
`"46@5
`o3" 1 
`   !
`F.,.;:<q+ 3'  1
`
`
`}
`' 
`  ! UW  
`1 4¸'  46@5$4¹'  46@5
`o3


` 
`1
`¾X[! !
`'   ! 
`0' 3'1½
`$D 
`0
` ! 45 46@5$4 46@5
`o3[
`  1 
`   ! U
`
` 
`0 W 
` 
`1
`¾ ! 


`C
` "1
` 3'1½  ! UW  
` 
`

   ‚6
`"$@
`"46@E
`oD &
`| D" 
`
` 


` ! 4}'  46@E
`o'  1
`
`
`¹
`'   ! UW  
`1 4¹$4}'  46@E
`o3ZX 
`0 ! '  ! U1 !¾
`
`!     
`D    !
` !0 ! 'W'
` !
`  3'  1
`
`
`¹
`
`'   ! UW  
`1¾[& 
` !
`#
`$% & 
` !
` 
`
`! 
`
`    D  4¹'  46@E
`o30
` 


`#
`$% & 
` !
`  
` 
`X  3
`
`
` !
`   
`¨


`
`  
`

'
`  @4 46@E
`o3'
` !
`D 
`[
` 

 ! '   | !1 ' 
`$
`W 
` 
`1
` 3
`
`  1!  ! U
` !
`  4‚$4E
`"46@‚
`o3 '
` " ¾  
`  
`
`! W ! 1  2 !
`'
` "

0  3'1
`'      5$¸¨46@‚
`o30 !W
`D 
`
`¾0  ! U
` 
`
`Â0  U  3'1
`
`'   ! UW  
`1 ¸$¹

46@‚
`o3#
`$% & 
` !
`  
`  
`
`!  3D &
`|  !  44$
`4‚'  46@‚
`o3[& 
` 
`
`
` !
`  3' 4¹" 

46@‚
`o31 1
`
` 1 
`    ! U1 ! 3'1 &
`'   ! U
`W  
`1 4E$45'  46@4
`o3
`   1
`  " $0

W"
`
` !¾X  
`  ! U1 ! 3'1 
`'   ! UW  
`1 ‚$E

46@@
`o3
` !
` !
`
` 'W' ¾0    
`  3'1
`'   ! U
`W  
`1 4¸$4¹'  46@6
`o "!½'      46@6
`o "!½'      466}
`o3
` !
` !
`
` 'W' ¾0    
`  3'10 '   ! U
`W  
`1 4¸$4¹'  466}
`o3 
`1  "
`  !
`  0 
` !
` !'
`
`
`1%
`
` !  ! U
`W  
` 3'11 466}
`o3
`
`  ! 
` !
` ¾
`
`! 
`1  
`%     
`Ã 
` 3%[
`
`  
`

X
` " 466¹
`o "!½'      466¹
`o31$  ! Y
`  3 Z 
`

  
`
`  
`

¨ 
`' 

   466¹
`o3  ! 
` !
`  
`%  Ã 
` 1 
` 3' 
` !
`466¹o3X


`
`
`
`'!
` 3%[
`
`  
`

X
` " 466¹
`
`o Symposium: Hot Topics in Life Sciences Law, 30 October 2015
`o "Obviousness Considerations in Light of BaracIude," American Conference |nstitute's 9th Annual
`Paragraph IV Disputes Conference, 27 April 2015 - 28 April 2015
`o "May It Please the Court: Rules of Engagement for Appearing Before the PTAB," AC|’s Post-Grant PTO
`Proceedings, 25 March 2015 - 26 March 2015
`o "Ethical Considerations for Paragraph IV Matters Before the PTO and District Courts: Looking Beyond
`Inequitable Conduct," AC|’s Paragraph IV Disputes Master Symposium, 30 September - 1 October 2014
`o G|axoSmithKline Global Patent Lawyers Meeting, 29 April 2014
`o American Conference |nstitute's 8th Annual Paragraph IV Disputes Conference, 28-29 April 2014
`o "Use of IPR and Other PTO Proceedings in A Paragraph IV Challenge: Strategies For Brand Names and
`Generics in Navigating PTO Proceedings in ANDA Litigation," American Conference |nstitute's 8th
`Annual Paragraph IV Disputes Conference: Expert Insights on Hatch-Waxman Litigation Strategies for
`Brand Names and Generics, 28 April 2014
`o "The Interplay Between Hatch-Waxman Litigation and Inter Partes Review," Patent Litigation Seminar
`— New Jersey Intellectual Property Law Association, 12 March 2014
`o "A Litigator's Guide to Effectively Preserving issues for Appeal and Keeping Your Case Alive Post-
`District Court," International Congress on Paragraph IV Litigation, 23-24 September 2013
`o "Monoclonal Antibodies: Successful and Practical Strategies for Developing and Commercializing
`Antibody Therapies," AC|'s Fourth Advanced Forum on Biosimilars, 5-7 June 2013
`o "Throwing Down the Gauntlet: The Paragraph IV Notice Letter-The Branded View," AC|'s Seventh
`Annual Paragraph IV Disputes Conference, 7-8 May 2013
`o "Hatch-Waxman Litigation Process Fundamentals and Strategies," G|axoSmithKline Law Program, 22-
`23 April 2013
`o "Experts in Patent Litigation," NYIPLA, 28 February 2013
`o "New Claim Construction Considerations in Paragraph IV Challenges," AC|'s Sixth Annual Paragraph IV
`Disputes Conference, 24-25 April 2012
`o "New Standards and Controversies in Obviousness-Type Double Patenting: Repercussions for
`Paragraph IV Challenges," AC|'s Fifth Annual Paragraph IV Disputes Conference, 3-4 May 2011
`o "Litigating with Multiple ANDA Filers: The Brand Name Perspective," AC|'s Fourth Annual Paragraph IV
`Disputes Conference, 27-28 April 2010
`o B|oomberg’s Annual Law Speaker Series, 2010
`o B|oomberg’s Annual Law Speaker Series, 2009
`o "Litigating with Multiple ANDA Filers: The Brand Name Perspective," AC|'s Third Annual Paragraph IV
`Disputes Conference, 27-28 April 2009
`o "Master Class, Obtaining Optimal Terms and Mitigating Antitrust Concerns When Settling Paragraph IV
`Disputes," ACI Conference, 2009
`o "Patent Licensing and Litigation: Strategies to Consider in the Wake of Medlmmune, Sandisk and
`Quanta," MWE Intellectual Property Roundtable, 2008
`o B|oomberg’s Annual Law Speaker Series, 2008
`o "Cross-Licensing and |njunctions," Fordham University School of Law, Intellectual Property Journal
`Annual Symposium, 2008
`o "Licensing and Litigation in the Wake of Medlmmune and Quanta Computer," IPO Annual Meeting,
`2008
`
`o "Reverse Payment Settlement Agreements," MWE Intellectual Property Roundtable, 2008
`
`–——˜™š’’›œ„Œ†ˆ›žˆœ’˜†ˆ˜Ÿ†’ †—„¡Ÿ˜¡—›„™˜¢£„——ˆ†Œ¤Š”¥
`
`https ://www.mayerbrown.com/people/detailprint.aspx?attomey=409
`
`‘’‡“’‘”‡•
`
`2/1 8/201 6